TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Twist Bioscience Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$139.77+7.02 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $8.72B
- P/E (TTM)
- –
- Dividend yield
- –
Twist Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Market Cap | $8.76B | $197.05M |
| Enterprise Value | $8.60B | $106.56M |
| PS Ratio | 20.30 | 3.93 |
| PB Ratio | 19.66 | 2.14 |
| P/TBV Ratio | 24.98 | 2.46 |
Enterprise value
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| EV / Sales | 19.91 | 2.69 |
Income (trailing twelve months)
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Revenue | $431.80M | $57.94M |
| Gross Profit | $224.39M | $90.47M |
| Operating Income | -$144.98M | -$21.44M |
| Pretax Income | -$135.85M | -$14.45M |
| Net Income | -$136.72M | -$22.46M |
| EBITDA | -$119.59M | -$16.91M |
| EPS (Diluted) | -$2.22 | -$0.83 |
Margins
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Gross Margin | 52.0% | 52.3% |
| Operating Margin | -33.6% | -44.5% |
| Pretax Margin | -31.5% | -13.0% |
| Profit Margin | -31.7% | -39.2% |
| EBITDA Margin | -27.7% | -31.3% |
| FCF Margin | -21.6% | -8.85% |
Returns
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -29.6% | -53.1% |
| Return on Assets (ROA) | -20.8% | -41.0% |
| Return on Invested Capital (ROIC) | -45.5% | -32.0% |
| Return on Capital Employed (ROCE) | -26.3% | -37.8% |
Growth
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 19.2% | 6.01% |
| Revenue Growth (3Y CAGR) | 22.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 33.1% | 6.42% |
Balance sheet
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $166.84M | $62.42M |
| Net Cash (Debt) | $166.84M | $15.68M |
| Net Cash Per Share | $2.66 | $0.65 |
| Equity (Book Value) | $445.74M | $48.79M |
| Book Value Per Share | $7.11 | $1.36 |
| Tangible Book Value | $350.81M | $23.06M |
| Working Capital | $201.04M | $75.77M |
Financial position
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Current Ratio | 2.67 | 3.30 |
| Quick Ratio | 1.93 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$53.07M | -$12.35M |
| Capital Expenditures | -$40.05M | -$1.06M |
| Free Cash Flow | -$93.12M | -$20.28M |
| FCF Per Share | -$1.49 | -$0.41 |
Efficiency
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 0.66 | 0.38 |
| Inventory Turnover | 6.79 | 2.67 |
| Revenue Per Employee | $441.06K | $398.96K |
| Profits Per Employee | -$139.65K | -$732.08K |
| Employee Count | 979 | 73 |
Dividends and yields
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -1.56% | -21.2% |
| FCF Yield | -1.06% | -7.64% |
Shares
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 62,707,400 | 59,128,900 |
| Shares Change (YoY) | 2.93% | 11.1% |
| Shares Change (QoQ) | 0.84% | 0.54% |
| Float | 61,238,700 | 48,744,500 |
| Shares Held by Insiders | 2.34% | 11.8% |
| Shares Held by Institutions | 121.8% | 59.4% |
Taxes
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Income Tax | $864.00K | $91.50K |
Scores
| Measure | Twist Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | 20.51 | 0.10 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -2.24 | -2.62 |
Calculated by StockData from Twist Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.